Federal Register / Vol. 82, No. 212 / Friday, November 3, 2017 / Notices 51293 

(‘‘the ’557 patent’’). The complaint 

further alleges that an industry in the 

United States exists as required by the 

applicable Federal Statute. 

The complainant requests that the 

Commission institute an investigation 

and, after the investigation, issue a 

limited exclusion order and cease and 

desist orders. 

ADDRESSES: The complaint, except for 

any confidential information contained 

therein, is available for inspection 

during official business hours (8:45 a.m. 

to 5:15 p.m.) in the Office of the 

Secretary, U.S. International Trade 

Commission, 500 E Street SW., Room 

112, Washington, DC 20436, telephone 

(202) 205–2000. Hearing impaired 

individuals are advised that information 

on this matter can be obtained by 

contacting the Commission’s TDD 

terminal on (202) 205–1810. Persons 

with mobility impairments who will 

need special assistance in gaining access 

to the Commission should contact the 

Office of the Secretary at (202) 205– 

2000. General information concerning 

the Commission may also be obtained 

by accessing its internet server at 

https://www.usitc.gov. The public 

record for this investigation may be 

viewed on the Commission’s electronic 

docket (EDIS) at https://edis.usitc.gov. 

FOR FURTHER INFORMATION CONTACT: 

Katherine Hiner, The Office of 

Secretary, Docket Services, U.S. 

International Trade Commission, 

telephone (202) 205–1802. 

SUPPLEMENTARY INFORMATION: 

Authority: The authority for 

institution of this investigation is 

contained in section 337 of the Tariff 

Act of 1930, as amended, 19 U.S.C. 1337 

and in section 210.10 of the 

Commission’s Rules of Practice and 

Procedure, 19 CFR 210.10 (2017). 

Scope of Investigation: Having 

considered the complaint, the U.S. 

International Trade Commission, on 

October 30, 2017, Ordered that— 

(1) Pursuant to subsection (b) of 

section 337 of the Tariff Act of 1930, as 

amended, an investigation be instituted 

to determine whether there is a 

violation of subsection (a)(1)(B) of 

section 337 in the importation into the 

United States, the sale for importation, 

or the sale within the United States after 

importation of certain wafer-level 

packaging semiconductor devices and 

products containing same (including 

cellular phones, tablets, laptops, and 

notebooks) and components thereof by 

reason of infringement of one or more of 

claims 1–8 of the ’557 patent and claims 

1–18 of the ’001 patent; and whether an 

industry in the United States exists as 

required by subsection (a)(2) of section 

337; 

(2) For the purpose of the 

investigation so instituted, the following 

are hereby named as parties upon which 

this notice of investigation shall be 

served: 

(a) The complainant is: Tessera 

Advanced Technologies, Inc., 3025 

Orchard Parkway, San Jose, CA 95134. 

(b) The respondents are the following 

entities alleged to be in violation of 

section 337, and are the parties upon 

which the complaint is to be served: 

Samsung Electronics Co., Ltd., 129 

Samsung-ro, Maetan-3dong, Yeongtonggu, Suwon-si, Gyeonggi-do, Republic of 

Korea 443–742. 

Samsung Electronics America, Inc., 85 

Challenger Road, Ridgefield Park, NJ 

07660. 

Samsung Semiconductor, Inc., 3655 

N. 1st Street, San Jose, CA 95134. 

(3) For the investigation so instituted, 

the Chief Administrative Law Judge, 

U.S. International Trade Commission, 

shall designate the presiding 

Administrative Law Judge. 

The Office of Unfair Import 

Investigations will not participate as a 

party in this investigation. 

Responses to the complaint and the 

notice of investigation must be 

submitted by the named respondents in 

accordance with section 210.13 of the 

Commission’s Rules of Practice and 

Procedure, 19 CFR 210.13. Pursuant to 

19 CFR 201.16(e) and 210.13(a), such 

responses will be considered by the 

Commission if received not later than 20 

days after the date of service by the 

Commission of the complaint and the 

notice of investigation. Extensions of 

time for submitting responses to the 

complaint and the notice of 

investigation will not be granted unless 

good cause therefor is shown. 

Failure of a respondent to file a timely 

response to each allegation in the 

complaint and in this notice may be 

deemed to constitute a waiver of the 

right to appear and contest the 

allegations of the complaint and this 

notice, and to authorize the 

administrative law judge and the 

Commission, without further notice to 

the respondent, to find the facts to be as 

alleged in the complaint and this notice 

and to enter an initial determination 

and a final determination containing 

such findings, and may result in the 

issuance of an exclusion order or a cease 

and desist order or both directed against 

the respondent. 

By order of the Commission. 

Issued: October 31, 2017. 

Lisa R. Barton, 

Secretary to the Commission. 

[FR Doc. 2017–24004 Filed 11–2–17; 8:45 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–470F] 

Final Adjusted Aggregate Production 

Quotas for Schedule I and II Controlled 

Substances and Assessment of 

Annual Needs for the List I Chemicals 

Ephedrine, Pseudoephedrine, and 

Phenylpropanolamine for 2017 

AGENCY: Drug Enforcement 

Administration (DEA), Department of 

Justice (DOJ). 

ACTION: Final order. 

SUMMARY: This final order establishes 

the final adjusted 2017 aggregate 

production quotas for controlled 

substances in schedules I and II of the 

Controlled Substances Act and the 

assessment of annual needs for the list 

I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine. 

DATES: This order is applicable 

November 3, 2017. 

FOR FURTHER INFORMATION CONTACT: 

Michael J. Lewis, Diversion Control 

Division, Drug Enforcement 

Administration, 8701 Morrissette Drive, 

Springfield, VA 22152, Telephone: (202) 

598–6812. 

SUPPLEMENTARY INFORMATION: 

Legal Authority 

Section 306 of the Controlled 

Substances Act (CSA) (21 U.S.C. 826) 

requires the Attorney General to 

establish aggregate production quotas 

for each basic class of controlled 

substances listed in schedules I and II 

and for the list I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine. The Attorney 

General has delegated this function to 

the Administrator of the Drug 

Enforcement Administration (DEA) 

pursuant to 28 CFR 0.100. 

Background 

The DEA published the 2017 

established aggregate production quotas 

for controlled substances in schedules I 

and II and for the assessment of annual 

needs for the list I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine in the Federal 

Register on October 5, 2016. 81 FR 

69079. This notice stated that the 


ethrower on DSK3G9T082PROD with NOTICES
51294 Federal Register / Vol. 82, No. 212 / Friday, November 3, 2017 / Notices 

Administrator would adjust, as needed, 

the established aggregate production 

quotas in 2017 in accordance with 21 

CFR 1303.13 and 21 CFR 1315.13. The 

2017 proposed adjusted aggregate 

production quotas for controlled 

substances in schedules I and II and 

assessment of annual needs for the list 

I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine were 

subsequently published in the Federal 

Register on August 4, 2017, (82 FR 

36449) in consideration of the outlined 

criteria. All interested persons were 

invited to comment on or object to the 

proposed adjusted aggregate production 

quotas and assessment of annual needs 

on or before September 5, 2017. 

Comments Received 

Three DEA-registered entities 

submitted timely comments regarding a 

total of eleven schedule I and II 

controlled substances. Comments 

received proposed that the aggregate 

production quotas for amphetamine (for 

conversion), dihydrocodeine, 

diphenoxylate (for sale), heroin, 

levorphanol, lisdexamfetmine, 

methadone intermediate, 

noroxymorphone (for conversion), 

oripavine, oxycodone (for sale), and 

oxymorphone (for conversion) were 

insufficient to provide for the estimated 

medical, scientific, research, and 

industrial needs of the United States, for 

export requirements, and for the 

establishment and maintenance of 

reserve stocks. The DEA received 43 

comments from non-DEA registered 

entities in response to the DEA’s August 

4, 2017, press release for the proposed 

2018 aggregate production quotas. The 

majority of these commenters expressed 

concerns about the 20 percent decrease 

to the production quotas of controlled 

substances. The DEA also received two 

comments from non-DEA registered 

entities suggesting that the rescheduling 

of marihuana would drastically reduce 

opioid use, misuse, and addiction. 

These 45 comments addressed issues 

that were outside the scope of this final 

order, and therefore are not relevant to 

the analysis involved in finalizing the 

2017 aggregate production quotas. 

The DEA received no comments from 

DEA-registered or non-DEA registered 

entities for previously established 

values of the 2017 assessment of annual 

needs for ephedrine, pseudoephedrine, 

and phenylpropanolamine. 

Analysis for Final Adjusted 2017 

Aggregate Production Quotas and 

Assessment of Annual Needs 

In determining the final adjusted 2017 

aggregate production quotas and 

assessment of annual needs, the DEA 

has taken into consideration the above 

comments that are specifically relevant 

to this Final Order for calendar year 

2017 along with the factors set forth in 

21 CFR 1303.13 and 21 CFR 1315.13 in 

accordance with 21 U.S.C. 826(a), and 

other relevant factors including the 2016 

year-end inventories, initial 2017 

manufacturing and import quotas, 2017 

export requirements, actual and 

projected 2017 sales, research and 

product development requirements, and 

additional applications received. Based 

on all of the above, the Administrator is 

adjusting the 2017 aggregate production 

quotas and assessment of annual needs 

for 4-Anilino-N-Phenethyl-4-Piperidine 

(ANPP), dihydrocodeine, ephedrine (for 

sale), fentanyl, hydrocodone (for sale), 

meperidine, methadone intermediate, 

morphine (for sale), opium (tincture), 

Oripavine, oxycodone (for sale), 

Oxymorphone (for conversion), 

Oxymorphone (for sale), 

phenylpropanolamine (for conversion), 

phenylpropanolamine (for sale), 

pseudoephedrine (for sale), tapentadol, 

and thiafentanil. This final order reflects 

those adjustments. 

Regarding diphenoxylate (for sale), 

heroin, levorphanol, and 

noroxymorphone (for conversion) the 

Administrator hereby determines that 

the proposed adjusted 2017 aggregate 

production quotas and assessment of 

annual needs for these substances and 

list I chemicals as published on August 

4, 2017, (82 FR 36449) are sufficient to 

meet the current 2017 estimated 

medical, scientific, research, and 

industrial needs of the United States 

and to provide for adequate reserve 

stock. This final order establishes these 

aggregate production quotas at the same 

amounts as proposed. 

Pursuant to the above, the 

Administrator hereby finalizes the 2017 

aggregate production quotas for the 

following schedule I and II controlled 

substances and the 2017 assessment of 

annual needs for the list I chemicals 

ephedrine, pseudoephedrine, and 

phenylpropanolamine, expressed in 

grams of anhydrous acid or base, as 

follows: 

Basic class 

Final revised 

2017 quotas 

(g) 

Schedule I 

1-(1-Phenylcyclohexyl)pyrrolidine ...................................................................................................................................................... 10 

1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) .......................................................................................................................... 30 

1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) ......................................................................................................................... 30 

1-[1-(2-Thienyl)cyclohexyl]piperidine ................................................................................................................................................. 15 

1-Benzylpiperazine ............................................................................................................................................................................ 25 

1-Methyl-4-phenyl-4-propionoxypiperidine ......................................................................................................................................... 2 

2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E) ......................................................................................................................... 30 

2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D) ...................................................................................................................... 30 

2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N) ........................................................................................................................ 30 

2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C-P) .................................................................................................................... 30 

2-(2,5-Dimethoxyphenyl)ethanamine (2C-H) ..................................................................................................................................... 30 

2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36) ...................... 25 

2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C) ...................................................................................................................... 30 

2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82) ...................... 25 

2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I) ............................................................................................................................ 30 

2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I–NBOMe; 2C-I–NBOMe; 25I; Cimbi-5) .............................. 30 

2,5-Dimethoxy-4-ethylamphetamine (DOET) .................................................................................................................................... 25 

2,5-Dimethoxy-4-n-propylthiophenethylamine ................................................................................................................................... 25 

2,5-Dimethoxyamphetamine .............................................................................................................................................................. 25 

2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2) .............................................................................................................. 30 

2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4) ........................................................................................................ 30 

3,4,5-Trimethoxyamphetamine .......................................................................................................................................................... 25 

3,4-Methylenedioxyamphetamine (MDA) .......................................................................................................................................... 55 


ethrower on DSK3G9T082PROD with NOTICES
Federal Register / Vol. 82, No. 212 / Friday, November 3, 2017 / Notices 51295 

Basic class 

Final revised 

2017 quotas 

(g) 

3,4-Methylenedioxymethamphetamine (MDMA) ............................................................................................................................... 50 

3,4-Methylenedioxy-N-ethylamphetamine (MDEA) ........................................................................................................................... 40 

3,4-Methylenedioxy-N-methylcathinone (methylone) ........................................................................................................................ 40 

3,4-Methylenedioxypyrovalerone (MDPV) ......................................................................................................................................... 35 

3-FMC; 3-Fluoro-N-methylcathinone ................................................................................................................................................. 25 

3-Methylfentanyl ................................................................................................................................................................................. 30 

3-Methylthiofentanyl ........................................................................................................................................................................... 30 

4-Bromo-2,5-dimethoxyamphetamine (DOB) .................................................................................................................................... 25 

4-Bromo-2,5-dimethoxyphenethylamine (2–CB) ............................................................................................................................... 25 

4-Fluoroisobutyryl fentanyl ................................................................................................................................................................. 30 

4-FMC; Flephedrone .......................................................................................................................................................................... 25 

4-MEC; 4-Methyl-N-ethylcathinone .................................................................................................................................................... 25 

4-Methoxyamphetamine .................................................................................................................................................................... 150 

4-Methyl-2,5-dimethoxyamphetamine (DOM) .................................................................................................................................... 25 

4-Methylaminorex .............................................................................................................................................................................. 25 

4-Methyl-N-methylcathinone (mephedrone) ...................................................................................................................................... 45 

4-Methyl-a-pyrrolidinopropiophenone (4-MePPP) ............................................................................................................................. 25 

5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol ....................................................................................................... 50 

5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47,497 C8-homolog) ......................... 40 

5F-ADB; 5F-MDMB-PINACA (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) .......................... 30 

5F-AMB (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate) ................................................................. 30 

5F-APINACA; 5F-AKB48 (N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide) ...................................................... 30 

5-Fluoro-PB-22; 5F-PB-22 ................................................................................................................................................................. 20 

5-Fluoro-UR144, XLR11 ([1-(5-fluoro-pentyl)-1Hindol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone .......................................... 25 

5-Methoxy-3,4-methylenedioxyamphetamine .................................................................................................................................... 25 

5-Methoxy-N,N-diisopropyltryptamine ................................................................................................................................................ 25 

5-Methoxy-N,N-dimethyltryptamine ................................................................................................................................................... 25 

AB-CHMINACA .................................................................................................................................................................................. 30 

AB-FUBINACA ................................................................................................................................................................................... 50 

AB-PINACA ........................................................................................................................................................................................ 30 

Acetyl Fentanyl .................................................................................................................................................................................. 100 

Acetyl-alpha-methylfentanyl ............................................................................................................................................................... 30 

Acetyldihydrocodeine ......................................................................................................................................................................... 30 

Acetylmethadol .................................................................................................................................................................................. 2 

ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) ................................ 30 

ADB-PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) .................................................... 50 

AH-7921 ............................................................................................................................................................................................. 30 

Allylprodine ........................................................................................................................................................................................ 2 

Alphacetylmethadol ............................................................................................................................................................................ 2 

alpha-Ethyltryptamine ........................................................................................................................................................................ 25 

Alphameprodine ................................................................................................................................................................................. 2 

Alphamethadol ................................................................................................................................................................................... 2 

alpha-Methylfentanyl .......................................................................................................................................................................... 30 

alpha-Methylthiofentanyl .................................................................................................................................................................... 30 

alpha-Methyltryptamine (AMT) .......................................................................................................................................................... 25 

alpha-Pyrrolidinobutiophenone (a-PBP) ............................................................................................................................................ 25 

alpha-Pyrrolidinopentiophenone (a-PVP) .......................................................................................................................................... 25 

Aminorex ............................................................................................................................................................................................ 25 

APINCA, AKB48 (N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide) ....................................................................................... 25 

Benzylmorphine ................................................................................................................................................................................. 30 

Betacetylmethadol ............................................................................................................................................................................. 2 

beta-Hydroxy-3-methylfentanyl .......................................................................................................................................................... 30 

beta-Hydroxyfentanyl ......................................................................................................................................................................... 30 

beta-Hydroxythiofentanyl ................................................................................................................................................................... 30 

Betameprodine ................................................................................................................................................................................... 2 

Betamethadol ..................................................................................................................................................................................... 4 

Betaprodine ........................................................................................................................................................................................ 2 

Bufotenine .......................................................................................................................................................................................... 3 

Butylone ............................................................................................................................................................................................. 25 

Butyryl Fentanyl ................................................................................................................................................................................. 30 

Cathinone ........................................................................................................................................................................................... 24 

Codeine Methylbromide ..................................................................................................................................................................... 30 

Codeine-N-oxide ................................................................................................................................................................................ 330 

Desomorphine .................................................................................................................................................................................... 25 

Diethyltryptamine ............................................................................................................................................................................... 25 

Difenoxin ............................................................................................................................................................................................ 8,750 

Dihydromorphine ................................................................................................................................................................................ 1,566,000 

Dimethyltryptamine ............................................................................................................................................................................ 35 

Dipipanone ......................................................................................................................................................................................... 5 

Etorphine ............................................................................................................................................................................................ 30 

Fenethylline ........................................................................................................................................................................................ 30 

Furanyl Fentanyl ................................................................................................................................................................................ 30 


ethrower on DSK3G9T082PROD with NOTICES
51296 Federal Register / Vol. 82, No. 212 / Friday, November 3, 2017 / Notices 

Basic class 

Final revised 

2017 quotas 

(g) 

gamma-Hydroxybutyric acid .............................................................................................................................................................. 56,200,000 

Heroin ................................................................................................................................................................................................ 45 

Hydromorphinol .................................................................................................................................................................................. 2 

Hydroxypethidine ............................................................................................................................................................................... 2 

Ibogaine ............................................................................................................................................................................................. 30 

JWH-018 and AM678 (1-Pentyl-3-(1-naphthoyl)indole) .................................................................................................................... 35 

JWH-019 (1-Hexyl-3-(1-naphthoyl)indole) ......................................................................................................................................... 45 

JWH-073 (1-Butyl-3-(1-naphthoyl)indole) .......................................................................................................................................... 45 

JWH-081 (1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole) ..................................................................................................................... 30 

JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole) ......................................................................................................................... 30 

JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole) ............................................................................................................. 35 

JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole) .......................................................................................................................... 30 

JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole) ...................................................................................................................... 30 

JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole) .......................................................................................................................... 30 

Lysergic acid diethylamide (LSD) ...................................................................................................................................................... 40 

MAB-CHMINACA; ADB-CHMINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3- 

carboxamide) .................................................................................................................................................................................. 30 

MDMB-CHMICA; MMB-CHMINACA(methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate) ............... 30 

MDMB-FUBINACA (methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) ......................................... 30 

Marihuana .......................................................................................................................................................................................... 472,000 

Mecloqualone ..................................................................................................................................................................................... 30 

Mescaline ........................................................................................................................................................................................... 25 

Methaqualone .................................................................................................................................................................................... 60 

Methcathinone ................................................................................................................................................................................... 25 

Methyldesorphine ............................................................................................................................................................................... 5 

Methyldihydromorphine ...................................................................................................................................................................... 2 

Morphine methylbromide ................................................................................................................................................................... 5 

Morphine methylsulfonate .................................................................................................................................................................. 5 

Morphine-N-oxide .............................................................................................................................................................................. 350 

N,N-Dimethylamphetamine ................................................................................................................................................................ 25 

Naphyrone ......................................................................................................................................................................................... 25 

N-Ethyl-1-phenylcyclohexylamine ...................................................................................................................................................... 5 

N-Ethylamphetamine ......................................................................................................................................................................... 24 

N-Hydroxy-3,4-methylenedioxyamphetamine .................................................................................................................................... 24 

Noracymethadol ................................................................................................................................................................................. 2 

Norlevorphanol ................................................................................................................................................................................... 55 

Normethadone ................................................................................................................................................................................... 2 

Normorphine ...................................................................................................................................................................................... 40 

para-Fluorofentanyl ............................................................................................................................................................................ 25 

Parahexyl ........................................................................................................................................................................................... 5 

PB-22; QUPIC ................................................................................................................................................................................... 20 

Pentedrone ........................................................................................................................................................................................ 25 

Pentylone ........................................................................................................................................................................................... 25 

Phenomorphan .................................................................................................................................................................................. 2 

Pholcodine ......................................................................................................................................................................................... 5 

Psilocybin ........................................................................................................................................................................................... 30 

Psilocyn .............................................................................................................................................................................................. 50 

SR-18 and RCS-8 (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole) ......................................................................................... 45 

SR-19 and RCS-4 (1-Pentyl-3-[(4-methoxy)-benzoyl]indole) ............................................................................................................ 30 

Tetrahydrocannabinols ...................................................................................................................................................................... 409,000 

Thiofentanil ........................................................................................................................................................................................ 25 

THJ-2201 ( [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone) .................................................................................. 30 

Tilidine ................................................................................................................................................................................................ 25 

Trimeperidine ..................................................................................................................................................................................... 2 

U-47700 ............................................................................................................................................................................................. 30 

UR-144 (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone .................................................................................... 25 

Schedule II 

1-Phenylcyclohexylamine .................................................................................................................................................................. 4 

1-Piperidinocyclohexanecarbonitrile .................................................................................................................................................. 4 

4-Anilino-N-phenethyl-4-piperidine (ANPP) ....................................................................................................................................... 1,050,000 

Alfentanil ............................................................................................................................................................................................ 4,200 

Alphaprodine ...................................................................................................................................................................................... 2 

Amobarbital ........................................................................................................................................................................................ 20,100 

Amphetamine (for conversion) .......................................................................................................................................................... 12,000,000 

Amphetamine (for sale) ..................................................................................................................................................................... 42,400,000 

Carfentanil .......................................................................................................................................................................................... 20 

Cocaine .............................................................................................................................................................................................. 103,400 

Codeine (for conversion) ................................................................................................................................................................... 40,000,000 

Codeine (for sale) .............................................................................................................................................................................. 45,000,000 

Dextropropoxyphene .......................................................................................................................................................................... 35 


ethrower on DSK3G9T082PROD with NOTICES
Federal Register / Vol. 82, No. 212 / Friday, November 3, 2017 / Notices 51297 

Basic class 

Final revised 

2017 quotas 

(g) 

Dihydrocodeine .................................................................................................................................................................................. 360,000 

Dihydroetorphine ................................................................................................................................................................................ 2 

Diphenoxylate (for conversion) .......................................................................................................................................................... 15,000 

Diphenoxylate (for sale) ..................................................................................................................................................................... 1,110,000 

Ecgonine ............................................................................................................................................................................................ 99,000 

Ethylmorphine .................................................................................................................................................................................... 30 

Etorphine Hydrochloride .................................................................................................................................................................... 32 

Fentanyl ............................................................................................................................................................................................. 1,350,000 

Glutethimide ....................................................................................................................................................................................... 2 

Hydrocodone (for conversion) ........................................................................................................................................................... 122,000 

Hydrocodone (for sale) ...................................................................................................................................................................... 51,900,000 

Hydromorphone ................................................................................................................................................................................. 5,140,800 

Isomethadone .................................................................................................................................................................................... 30 

Levo-alphacetylmethadol (LAAM) ...................................................................................................................................................... 5 

Levomethorphan ................................................................................................................................................................................ 30 

Levorphanol ....................................................................................................................................................................................... 12,900 

Lisdexamfetamine .............................................................................................................................................................................. 19,000,000 

Meperidine ......................................................................................................................................................................................... 2,904,000 

Meperidine Intermediate-A ................................................................................................................................................................ 5 

Meperidine Intermediate-B ................................................................................................................................................................ 30 

Meperidine Intermediate-C ................................................................................................................................................................ 5 

Metazocine ......................................................................................................................................................................................... 15 

Methadone (for sale) ......................................................................................................................................................................... 23,700,000 

Methadone Intermediate .................................................................................................................................................................... 28,700,000 

Methamphetamine ............................................................................................................................................................................. 1,539,100 

[900,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 600,000 grams for methamphetamine mostly for 

conversion to a schedule III product; and 39,100 grams for methamphetamine (for sale)] 

Methylphenidate ................................................................................................................................................................................. 73,000,000 

Morphine (for conversion) .................................................................................................................................................................. 27,300,000 

Morphine (for sale) ............................................................................................................................................................................ 35,000,000 

Nabilone ............................................................................................................................................................................................. 19,000 

Noroxymorphone (for conversion) ..................................................................................................................................................... 17,700,000 

Noroxymorphone (for sale) ................................................................................................................................................................ 400,000 

Opium (powder) ................................................................................................................................................................................. 90,000 

Opium (tincture) ................................................................................................................................................................................. 500,000 

Oripavine ............................................................................................................................................................................................ 28,900,000 

Oxycodone (for conversion) .............................................................................................................................................................. 2,610,000 

Oxycodone (for sale) ......................................................................................................................................................................... 101,500,000 

Oxymorphone (for conversion) .......................................................................................................................................................... 23,000,000 

Oxymorphone (for sale) ..................................................................................................................................................................... 3,600,000 

Pentobarbital ...................................................................................................................................................................................... 27,500,000 

Phenazocine ...................................................................................................................................................................................... 5 

Phencyclidine ..................................................................................................................................................................................... 35 

Phenmetrazine ................................................................................................................................................................................... 25 

Phenylacetone ................................................................................................................................................................................... 40 

Racemethorphan ............................................................................................................................................................................... 5 

Racemorphan .................................................................................................................................................................................... 5 

Remifentanil ....................................................................................................................................................................................... 3,000 

Secobarbital ....................................................................................................................................................................................... 172,002 

Sufentanil ........................................................................................................................................................................................... 4,000 

Tapentadol ......................................................................................................................................................................................... 18,600,000 

Thiafentanil ........................................................................................................................................................................................ 30 

Thebaine ............................................................................................................................................................................................ 100,000,000 

List I Chemicals 

Ephedrine (for conversion) ................................................................................................................................................................ 50,000 

Ephedrine (for sale) ........................................................................................................................................................................... 4,810,000 

Phenylpropanolamine (for conversion) .............................................................................................................................................. 13,600,000 

Phenylpropanolamine (for sale) ......................................................................................................................................................... 7,000,000 

Pseudoephedrine (for conversion) .................................................................................................................................................... 40 

Pseudoephedrine (for sale) ............................................................................................................................................................... 186,000,000 


ethrower on DSK3G9T082PROD with NOTICES
51298 Federal Register / Vol. 82, No. 212 / Friday, November 3, 2017 / Notices 

Aggregate production quotas for all 

other schedule I and II controlled 

substances included in 21 CFR 1308.11 

and 1308.12 remain at zero. 

Dated: October 27, 2017. 

Robert W. Patterson, 

Acting Administrator. 

[FR Doc. 2017–24009 Filed 11–2–17; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Importer of Controlled Substances 

Application: Rhodes Technologies 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before December 4, 2017. Such 

persons may also file a written request 

for a hearing on the application on or 

before December 4, 2017. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DRW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for hearing must be 

sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All requests for hearing 

should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/LJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DRW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

Comments and requests for hearings on 

applications to import narcotic raw 

material are not appropriate. 72 FR 3417 

(January 25, 2007). 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Assistant 

Administrator of the DEA Diversion 

Control Division (‘‘Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.34(a), this is notice that on March 

17, 2017, Rhodes Technologies, 498 

Washington Street, Coventry, Rhode 

Island 02816 applied to be registered as 

an importer the following basic classes 

of controlled substances: 

Controlled 

substance Drug code Schedule 

Tetrahydrocannabinols.7370 I 

Methylphenidate 1724 II 

Oxycodone ....... 9143 II 

Hydromorphone 9150 II 

Hydrocodone .... 9193 II 

Morphine ........... 9300 II 

Oxymorphone ... 9652 II 

Opium, raw ....... 9600 II 

Poppy Straw 

Concentrate.

9670 II 

The company plans to import opium, 

raw (9600) and poppy straw concentrate 

(9670) in order to bulk manufacture 

controlled substances in Active 

Pharmaceutical Ingredient (API) form. 

The company distributes the 

manufactured APIs in bulk to its 

customers. The company plans to 

import the other listed controlled 

substances for internal reference 

standards use only. The comparisons of 

foreign reference standards to the 

company’s domestically manufacture 

API will allow the company to export 

domestically manufacture API to foreign 

markets. 

Dated: October 31, 2017. 

Demetra Ashley, 

Acting Assistant Administrator. 

[FR Doc. 2017–24012 Filed 11–2–17; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Notice of Lodging of Proposed 

Consent Decree Under the Clean Air 

Act 

On October 27, 2017, the Department 

of Justice lodged a proposed Consent 

Decree with the United States District 

Court for the Northern District of Ohio 

in the lawsuit entitled United States and 

the State of Ohio v. United Rolls Inc., 

Civil Action No. 5:17–cv–02278. 

The United States and the State of 

Ohio filed a Complaint seeking civil 

penalties and injunctive relief from 

Defendant United Rolls Inc. for alleged 

violations of the Clean Air Act, 42 

U.S.C. 7401–7671q, and corresponding 

provisions of Ohio’s air pollution 

control laws at United Rolls’ iron 

foundry facility in Canton, Ohio. The 

Complaint alleges violations of 

recordkeeping and reporting 

requirements, as well as failure to meet 

requirements for the control of 

particulate matter emissions from 

United Rolls’ facility. The proposed 

Consent Decree would require United 

Rolls to perform emissions testing, 

upgrade an air pollution control 

monitoring system, and take other steps 

to control air pollutant emissions from 

its Canton facility. United Rolls also 

would pay a total of $310,000 in civil 

penalties (with $186,000 payable to the 

United States and $124,000 payable to 

the State). 

The publication of this notice opens 

a period for public comment on the 

proposed Consent Decree. Comments 

should be addressed to the Acting 

Assistant Attorney General, 

Environment and Natural Resources 

Division, and should refer to United 

States and the State of Ohio v. United 

Rolls Inc., D.J. Ref. No. 90–5–2–1– 

10704. All comments must be submitted 

no later than thirty (30) days after the 

publication date of this notice. 

Comments may be submitted either by 

email or by mail: 

To submit 

comments: Send them to: 

By email ....... pubcomment-ees.enrd@

usdoj.gov. 

By mail ......... Assistant Attorney General, 

U.S. DOJ—ENRD, P.O. 

Box 7611, Washington, DC 

20044–7611. 

During the public comment period, 

the proposed Consent Decree may be 

examined and downloaded at this 

Justice Department Web site: https://

www.justice.gov/enrd/consent-decrees. 

We will provide a paper copy of the 

Consent Decree upon written request 

and payment of reproduction costs. 

Please mail your request and payment 

to: Consent Decree Library, U.S. DOJ— 

ENRD, P.O. Box 7611, Washington, DC 

20044–7611. 

Please enclose a check or money order 

for $16.25 (25 cents per page 

reproduction cost) payable to the United 

States Treasury. 

Randall M. Stone, 

Acting Assistant Section Chief, 

Environmental Enforcement Section, 

Environment and Natural Resources Division. 

[FR Doc. 2017–23915 Filed 11–2–17; 8:45 am] 

BILLING CODE 4410–15–P 


ethrower on DSK3G9T082PROD with NOTICES